Loading
ET
Eidos Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by AGUIAR ERIC, was filed 08 Jul 2019.
Eidos Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Eidos Therapeutics, Inc. as filed with SEC (Form 4). Nothing new has been filed by managers of Eidos Therapeutics, Inc. in twelve months, the latest record being from 16 December 2020.
Over the whole record (from 2018), the tally stands at 15 purchases and 111 sales.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
181
Thresholds
n/a
Buy Volume
€308M
15 ops. · all time
Sell Volume
€23M
111 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2019FY ended December 2019 · cache
Income statement
Revenue23.8M
Net income-33.7M-141.8% margin
Last declaration on 16 December 2020
Declarations181 total
4,451 shares@ US$17.001.0% of flowCommon StockSEC:0000899243-20-034181:0
21,843 shares@ US$13.203.8% of flowCommon StockSEC:0000899243-20-034181:1
3,756 shares@ US$110.29065.5% of flowCommon StockSEC:0000899243-20-034181:2
7,600 shares@ US$111.307511.2% of flowCommon StockSEC:0000899243-20-034181:3
11,445 shares@ US$112.190316.9% of flowCommon StockSEC:0000899243-20-034181:4
3,493 shares@ US$112.96575.2% of flowCommon StockSEC:0000899243-20-034181:5
3,005 shares@ US$73.5643.0% of flowCommon StockSEC:0000899243-20-031006:0
9,497 shares@ US$74.74579.6% of flowCommon StockSEC:0000899243-20-031006:1
908 shares@ US$75.22860.9% of flowCommon StockSEC:0000899243-20-031006:2
1,500 shares0Common StockSEC:0000899243-20-031006:3
1,623 shares@ US$7.240.7% of flowCommon StockSEC:0000899243-20-030728:0
1,623 shares@ US$74.92877.4% of flowCommon StockSEC:0000899243-20-030728:1
5,000 shares@ US$13.200.9% of flowCommon StockSEC:0000899243-20-030216:0
2,500 shares@ US$17.000.6% of flowCommon StockSEC:0000899243-20-030216:1
9,145 shares@ US$70.44388.9% of flowCommon StockSEC:0000899243-20-030216:2
3,146 shares@ US$71.41673.1% of flowCommon StockSEC:0000899243-20-030216:3
209 shares@ US$72.09610.2% of flowCommon StockSEC:0000899243-20-030216:4
5,000 shares@ US$7.242.2% of flowCommon StockSEC:0000899243-20-027918:0
5,444 shares@ US$75.082325.0% of flowCommon StockSEC:0000899243-20-027918:1
25 of 181 declarations
About Eidos Therapeutics, Inc.
Eidos Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for genetic diseases. It is listed on NASDAQ under the ticker symbol EIDX.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
